The U.S. Food and Drug Administration (FDA) has announced that the supply shortages of Eli Lilly's (LLY, Financial) popular weight-loss and diabetes medications, Zepbound and Mounjaro, have been resol
The U.S. Food and Drug Administration (FDA) recently announced that the shortage of Eli Lilly's weight loss medications, Mounjaro and Zepbound, has been resolved. While these drugs, which contain tirz
Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are no longer in shortage, the U.S. Food and Drug Administration's website showed on Wednesday.

3-Stock Lunch: Nike, Humana & Eli Lilly

03:07pm, Wednesday, 02'nd Oct 2024
Anthony Forcione, Rockland Trust VP, joins 'Power Lunch' to discuss stock plays for three stocks.
CNBC's Angelica Peebles joins 'Squawk on the Street' to report on Eli Lilly's new investment in a new $4.5 billion research and development center.
Eli Lilly and Co LLY is making a major move with a $4.5 billion investment to create the Lilly Medicine Foundry, a new research and manufacturing facility.

3 Momentum Trades Too Good Pass Up

08:36am, Wednesday, 02'nd Oct 2024
Momentum investing is based on the idea that stocks that have risen recently will tend to keep rising and that stocks that have fallen tend to keep falling. In 1993, researchers Narasimhan Jegadeesh a
CNBC's Angelica Peebles joins 'Squawk Box' with the latest news.
U.S. drugmaker Eli Lilly said on Wednesday it will invest $4.5 billion to create a new center for advanced manufacturing and drug development in Indiana.
Eli Lilly will invest $4.5 billion to construct the Lilly Medicine Foundry, a center aimed at finding better ways to make medicines. The investment seeks to build upon Lilly's success from Mounjaro an
Indiana facility will combine research, manufacturing and the latest technology to innovate new production methods and scale global access to clinical supply for Lilly's growing pipeline Opening in la
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Eli Lilly received FDA approval for Ebglyss for the treatment of moderate to severe atopic dermatitis this month. Ebglyss' efficacy looks comparable, if not slightly superior, to current market leader
The fundamentals of high-quality stocks, from a fund manager who handily beats the market.
For income investors, closed-end funds remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. Closed-end funds, or CEFs,
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE